Caremark ( CMX) insiders are whistling a scary tune. In an updated complaint filed this month, Caremark employees have bolstered fraud allegations levied against the giant pharmacy benefit manager. The amended whistleblower lawsuit, filed by two Caremark pharmacists on behalf of Florida customers, suggests that the company has routinely "placed profits and expediency in front of patient safety, ethical and honest business practices and false claims laws." The lawsuit, originally filed last year , extends its portrayal of Caremark -- the nation's second-largest PBM -- as a company that has taken deliberate, and sometimes extreme, steps to boost its bottom line. Specifically, the complaint accuses the company of failing to properly fill prescriptions and then snagging bonuses, instead of penalties, for its performance. Citing new insider testimony, the complaint even accuses Caremark of defrauding some of the company's sickest customers. It claims the company improperly canceled refills for chronically ill patients who found themselves saddled with additional co-payments as a result. "Incredibly, Caremark's employees even targeted for refill elimination patients who are quadriplegics and who had therefore been prescribed prescription drugs on a long-term or lifetime basis," the complaint states. "The fraudulent practices ... are at the very least the indirect result of the fact that Caremark financially incentivized its employees to engage in such conduct." The plaintiffs have accused Caremark of, among other things, changing, canceling and even illegally reselling prescriptions in order to maximize profits. The complaint, featuring testimony from multiple insiders, continues to grow more detailed in nature. "We have done extensive investigations and discovery," said Michael Leonard, the Chicago attorney representing Caremark pharmacists Michael and Peppi Fowler. "It has been quite fruitful so far." Contacted by TheStreet.com on Thursday, Caremark continued to maintain its innocence. The company says it has "always been in compliance with applicable state regulations" -- and has even invited Florida, in particular, to review its activities. "We're in regular contact with the state of Florida regarding the issues raised," said Caremark spokesman Gerard Carney. "From the outset, we have welcomed any formal review or audit of our services on the state's behalf as we are confident about the outcome of any such proceedings." Caremark's stock -- which has nearly doubled over the past year -- slipped 33 cents Friday to hit $34.40.